KRYS Share Price Performance
KRYS Community Fair Values
- US$207.90FV24.5% undervalued intrinsic discount37.11%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative15users have followed this narrative3 days ago author updated this narrative
- US$176.00FV10.8% undervalued intrinsic discount17.70%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative1users have followed this narrative10 days ago author updated this narrative
- US$252.00FV37.7% undervalued intrinsic discount54.71%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative10 days ago author updated this narrative
Recent KRYS News & Updates
No updates
Krystal Biotech, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 04, 2025
- Earnings per share (EPS)
- 4.29
- Gross Margin
- 93.20%
- Net Profit Margin
- 37.18%
- Debt/Equity Ratio
- 0%
Krystal Biotech, Inc. Competitors
About KRYS
- Founded
- 2016
- Employees
- 275
- CEO
- WebsiteView website
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.1%
- 1 Year: 17.7%
- Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading